Skip to search formSkip to main contentSkip to account menu

biphasic human insulin 30

Known as: BHI 30 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Biphasic InsulinsDrug Combinationsinsulin, isophane

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Biphasic human insulin 30 thrice daily, is it reasonable?
To evaluate the efficacy and safety of thrice daily Biphasic Human Insulin 30 (BHI 30) versus the traditional twice-daily regimen… 
2013
2013
Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30 : Results from the Filipino cohort of the A 1 chieve study
Aim: To evaluate the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in Filipino patients with type 2 diabetes… 
2011
2011
Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving biphasic insulin aspart 30 or biphasic human insulin 30
Aims/Introduction:  Biphasic insulin aspart 30 (BIAsp 30) has an earlier and stronger peak effect with a similar duration of… 
2011
2011
Clinical effectiveness of biphasic insulin aspart 30:70 versus biphasic human insulin 30 in UK general clinical practice: a retrospective database study.
2010
2010
Switching to Biphasic Insulin Aspart 30 in Patients Uncontrolled on Human Premix Insulin
Two cases relating to switching from biphasic human insulin 30 (BHI 30) to biphasic insulin aspart 30 (BIAsp 30) are described… 
Review
2007
Review
2007
Biphasic Insulin Aspart in Type 2 Diabetes Mellitus
The efficacy benefits of biphasic insulin aspart formulation (BIAsp 30) in patients with diabetes mellitus have been reported in… 
2005
2005
Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin regimens (results from the Austrian Biaspart Study).
OBJECTIVE Major advantages of modern insulin regimens containing premixed insulin analogues in comparison to traditional insulin… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)